These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9582604)

  • 21. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer.
    Reale MG; Santini D; Marchei GG; Manna A; Del Nero A; Bianco V; Marchei P; Frati L
    Int J Biol Markers; 1995; 10(1):42-6. PubMed ID: 7629426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
    Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
    Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of bone scintigraphy for early detection of bone metastasis from breast cancer].
    Wada T; Hohjoh T; Matunami N; Yamato M; Kadota K; Morikawa E; Hara S; Matsuda T; Yasutomi M
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):781-5. PubMed ID: 2778373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
    Pecking AP; Mechelany-Corone C; Pichon MF
    Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer.
    Kasem AR; Desai A; Daniell S; Sinha P
    Breast J; 2006; 12(6):544-8. PubMed ID: 17238984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer.
    Prior JO; Barghouth G; Delaloye JF; Leyvraz S; Bischof Delaloye A
    Nucl Med Commun; 2003 Jan; 24(1):29-36. PubMed ID: 12501017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSA and bone scintigraphy.
    Modoni S; Calò E; Nardella G; Ritrovato G; Frusciante V
    Int J Biol Markers; 1997; 12(4):158-61. PubMed ID: 9582605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
    Tomlinson IP; Whyman A; Barrett JA; Kremer JK
    Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.